Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury

Oh, Binna; Lee, Minhyung

doi:10.1016/j.jconrel.2013.12.008

Cited by 51 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Premixture of siRNA and HMGB1A was found to be advantageous to avoid aggregate formation and to form particles below 200 nm that mediate an anti-inflammatory effect. Interestingly, the synergistic effect of co-delivery was more pronounced regarding cytokine levels in the lung lavage fluid compared to the lung tissue samples [124]. Baoum et al used a CPP, namely the HI-virus derived motif TAT and a longer ‘double’ TAT (dTAT) for the delivery of siRNA.…”

Section: Nanocarrier Chemistrymentioning

confidence: 99%

“…Amongst the studies discussed here, 15 ones used the i.t. route with [35, 67, 87] or without aerosolization [31, 37, 39, 42, 86, 89, 108, 119, 124, 134, 142, 143]. Another local and less invasive route for easily accessible administration of siRNA is the application of a nasal suspension in the nasal cavity.…”

Section: Administration Routementioning

confidence: 99%

“…ALI is another disease that is strongly researched in animal models as it can be rather easily induced by infection with lipopolysaccharide (LPS) after hemorrhage [37, 42, 119, 124, 143]. In regards to siRNA delivery, five papers are discussed here that are mostly interested in identifying novel targets that can be therapeutically downregulated to reduce the secretion of pro-inflammatory cytokines.…”

Section: Disease Modelsmentioning

confidence: 99%

“…In regards to siRNA delivery, five papers are discussed here that are mostly interested in identifying novel targets that can be therapeutically downregulated to reduce the secretion of pro-inflammatory cytokines. Peptides [124], polymers [119], viruses [42], even free nucleic acids [37, 143] have been used to achieve this effect. The results obtained with free siRNA that was administered locally were controversial between different papers.…”

Section: Disease Modelsmentioning

confidence: 99%

See 3 more Smart Citations

siRNA Delivery to the lung: What's new?

Merkel

Rubinstein

Kissel

2014

Advanced Drug Delivery Reviews

115

View full text Add to dashboard Cite

RNA interference (RNAi) has been thought of as the general answer to many unmet medical needs. After the first success stories, it soon became obvious that short interfering RNA (siRNA) is not suitable for systemic administration due to its poor pharmacokinetics. Therefore local administration routes have been adopted for more successful in vivo RNAi. This paper reviews nucleic acid modifications, nanocarrier chemistry, animal models used in successful pulmonary siRNA delivery, as well as clinical translation approaches. We summarize what has been published recently and conclude with the potential problems that may still hamper the efficient clinical application of RNAi in the lung.

show abstract

Section: Nanocarrier Chemistrymentioning

confidence: 99%

Section: Administration Routementioning

confidence: 99%

Section: Disease Modelsmentioning

confidence: 99%

Section: Disease Modelsmentioning

confidence: 99%

See 2 more Smart Citations

siRNA Delivery to the lung: What's new?

Merkel

Rubinstein

Kissel

2014

Advanced Drug Delivery Reviews

115

View full text Add to dashboard Cite

show abstract

“…To demonstrate the protective role of the PIC micelles against siRNA degradation, the PIC micelles of COOH-PEG-g-PAHy-GTA/ siRNA were prepared as described above [21]. FBS was added to the PIC micelles at a 50% final concentration.…”

Section: Serum Stability Studymentioning

confidence: 99%

Polyion complex micelles composed of pegylated polyasparthydrazide derivatives for siRNA delivery to the brain

Huo

Gao

Wang

et al. 2015

Journal of Colloid and Interface Science

View full text Add to dashboard Cite

The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

Dua

Wadhwa

Singhvi

et al. 2019

Drug Development Research

141

View full text Add to dashboard Cite

Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti‐inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post‐transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro‐inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.

show abstract

Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury

Cited by 51 publications

References 29 publications

siRNA Delivery to the lung: What's new?

siRNA Delivery to the lung: What's new?

Polyion complex micelles composed of pegylated polyasparthydrazide derivatives for siRNA delivery to the brain

The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

Contact Info

Product

Resources

About